Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Integrated genetic diagnostics of patients with early onset de novo MDS

Enrico Attardi, MD, University of Rome Tor Vergata, Rome Italy, comments on the results of a study using low-coverage whole-genome sequencing (WGS) on plasma cell-free DNA (cf-DNA) to define the molecular and cytogenetic characteristics of patients with early onset de novo myelodysplastic syndromes (MDS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.